Carret Asset Management LLC Sells 375 Shares of Illumina, Inc. (NASDAQ:ILMN)

Carret Asset Management LLC reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,465 shares of the life sciences company’s stock after selling 375 shares during the period. Carret Asset Management LLC’s holdings in Illumina were worth $201,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. Trivant Custom Portfolio Group LLC grew its stake in Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the period. VisionPoint Advisory Group LLC grew its position in Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after buying an additional 193 shares during the period. Wetzel Investment Advisors Inc. purchased a new stake in Illumina during the fourth quarter worth about $37,000. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 86.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares during the last quarter. Finally, Gradient Investments LLC raised its position in Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 225 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $105.28 on Thursday. The business has a 50-day moving average of $110.95 and a 200-day moving average of $126.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $195.64.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.08 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 0.98 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ILMN. TD Cowen decreased their price target on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Robert W. Baird upped their price target on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a report on Tuesday, May 7th. Finally, StockNews.com began coverage on Illumina in a research note on Sunday. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $157.62.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.